30126
document
[ Effect of alpha dihydroergocryptine in patients with fibrocystic breast disease ] . OBJECTIVE To evaluate the effectiveness of alpha dihidroergocriptine in patients with fibrocystic mastopathy . PATIENTS AND METHODS Patients with diagnosis of fibrocystic breast disease were included in a prospective longitudinal blind double , controlled with placebo study . Patients were randomly assigned to one of two treatment groups : of treatment group A : Alpha dihidroergocriptine tablets of 10 mg , group B : Placebo , during 6 months . After to basal evaluation , the patients were revised in a monthly way evaluating the following symptoms and signs : mastalgia , mammary tension , presence of nodules , nipple secretion , and the presence of adverse events . RESULTS 39 patients with alpha dihidroergocriptine and 38 with placebo . Mastodinia , a satisfactory response was observed in 100 % of alpha dihidroergocriptine group vs 61.11 % of placebo group ( p = 0.0002 ) . Mastalgia responded in 100 % of alpha dihidroergocriptine group vs 64.86 % of placebo group ( p = 0.0003 ) . Galactorrea responded 100 % of alpha dihidroergocriptine group vs 93.33 % of the placebo . The nodules in the group alpha dihidroergocriptine disappeared in 23.1 % and in 21.1 % of the placebo group . Ultrasound evaluation of the nodules did not show significant differences between both groups . Prolactin levels showed a decrease in the group treated with alpha dihidroergocriptine with an important difference between both groups at the end of the 6 months study period . There were not differences in the presence of adverse events between groups . CONCLUSIONS Alpha dihidroergocriptine is effective in the treatment of fribrocystic breast disease with minimum adverse events when compared with similar drugs .
30127
Intervention_Pharmacological
alpha dihydroergocryptine
30128
Intervention_Pharmacological
alpha dihidroergocriptine
30129
Intervention_Control
placebo
30130
Intervention_Pharmacological
Alpha dihidroergocriptine tablets of 10 mg
30131
Intervention_Control
Placebo
30132
Intervention_Pharmacological
alpha dihidroergocriptine
30133
Intervention_Control
placebo
30134
Intervention_Pharmacological
alpha dihidroergocriptine
30135
Intervention_Control
placebo
30136
Intervention_Pharmacological
alpha dihidroergocriptine
30137
Intervention_Pharmacological
alpha dihidroergocriptine
30138
Intervention_Pharmacological
Alpha dihidroergocriptine
30139
Outcome_Physical
mastalgia
30140
Outcome_Physical
mammary tension
30141
Outcome_Physical
presence of nodules
30142
Outcome_Physical
nipple secretion
30143
Outcome_Adverse-effects
presence of adverse events
30144
Outcome_Physical
Mastodinia
30145
Outcome_Physical
Mastalgia
30146
Outcome_Physical
Galactorrea
30147
Outcome_Physical
nodules
30148
Outcome_Physical
Prolactin levels
30149
Outcome_Adverse-effects
presence of adverse events
30150
Participant_Condition
patients with fibrocystic breast disease
30151
Participant_Condition
patients with fibrocystic mastopathy
30152
Participant_Condition
fibrocystic breast disease
30153
Participant_Sample-size
39
30154
Participant_Condition
alpha dihidroergocriptine
30155
Participant_Sample-size
38
30156
Participant_Condition
placebo
30157
Participant_Condition
fribrocystic breast disease